Comparison of efficacy and safety of different add-back drugs during GnRH-a administration for patients with endometriosis
LI Xueying
XIAO Li
HUANG Wei
FENG Xue
FU Jing
RUAN jie
CHEN Hengxi
YANG Shiyuan
Abstract：Objective To compare the efficacy and safety of add-back drug during GnRH-a administration for patients with endometriosis after laparoscopic treatment.Methods Totally 135 women with stage Ⅱ-Ⅳ endometriosis or adenomyoma were randomly assigned into Angeliq group,Tibolone group and Kuntai Capsule group,45 cases in each group.All patients received injection of Diphereline (3.75 mg) on the first day of menstruation,once every 4 weeks for 3 times.They took Angeliq,Tibolone or Kuntai Capsule respectively since the second injection for 8 weeks.Kupperman menopausal index (KMI),serum estradiol (E2) and follicle stimulating hormone (FSH),and ultrasound endometrial thickness were observed and compared.Results At the 4th and 12th week,KMI was comparable among three groups (P＞0.05).KMI at the 12th week was significantly lower than KMI at the 4th week in three groups (P=0.000).Serum E2 and FSH levels,and endometrial thickness had no significant difference among three groups (P＞ 0.05).Conclusion The three kinds of add-back drugs can effectively relieve the low-estrogenic symptoms induced by GnRH-a during medical therapy for endometriosis.
Keywords：endometriosisgonadotropin-releasing hormone agonistadd-back therapy
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 605-608 )